Form 4: Viridian Therapeutics Executive Thomas Beetham Reports Stock Option and RSU Grant

Thomas Beetham, Chief Operating Officer of Viridian Therapeutics, reports the acquisition of stock options and restricted stock units (RSUs) on March 3, 2025.

Summary

• On March 3, 2025, Thomas W. Beetham, Chief Operating Officer of Viridian Therapeutics, Inc., reported changes in beneficial ownership to the SEC.
• Beetham acquired 225,814 stock options with an exercise price of $14.41, vesting in 48 equal monthly installments starting March 3, 2025, and expiring on March 3, 2035.
• He also acquired 37,636 restricted stock units (RSUs), which vest over a four-year period, with 25% vesting annually starting March 3, 2025.
• Both the stock options and RSUs are subject to continued service with Viridian Therapeutics.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The granting of equity suggests confidence in the company's future, but it's a routine event.

Positives

• The grant of stock options and RSUs to the COO aligns his interests with those of the shareholders.
• The vesting schedule incentivizes continued service and commitment to the company's long-term success.

Risks

• The value of the stock options and RSUs is dependent on the future performance of Viridian Therapeutics' stock.
• If Beetham leaves the company before the options and RSUs fully vest, he will forfeit the unvested portion.

Future Outlook

The document does not contain specific forward-looking statements regarding the company's future performance, but the equity grants suggest an expectation of continued growth and value creation.

Industry Context

Equity grants are a common practice in the biotechnology industry to attract, retain, and incentivize key executives. These grants align management's interests with those of shareholders, encouraging them to drive long-term value creation.

Comparison to Industry Standards

• Equity compensation practices vary across the biotechnology industry, but stock options and RSUs are standard components of executive compensation packages.
• Companies like Amgen, Regeneron, and Biogen also utilize similar equity-based incentives to align executive compensation with shareholder value.
• The vesting schedules and grant sizes are generally benchmarked against peer companies to ensure competitiveness.

Stakeholder Impact

• Shareholders may view the equity grants positively as they align management's interests with long-term value creation.
• Employees may be motivated by the potential for future equity grants based on performance.

Key Dates